{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:48:51Z","timestamp":1761896931973,"version":"build-2065373602"},"reference-count":52,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T00:00:00Z","timestamp":1543449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005739","name":"Universidad Nacional Aut\u00f3noma de M\u00e9xico","doi-asserted-by":"publisher","award":["PAPIIT IN-225014,  IN209916"],"award-info":[{"award-number":["PAPIIT IN-225014,  IN209916"]}],"id":[{"id":"10.13039\/501100005739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","award":["154557"],"award-info":[{"award-number":["154557"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Instituto Nacional de Cancerolog\u00eda","award":["(017\/027\/IBI)(CEI\/1147\/17)"],"award-info":[{"award-number":["(017\/027\/IBI)(CEI\/1147\/17)"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Malignant pleural mesothelioma (MPM) is the most common tumor of the pulmonary pleura. It is a rare and aggressive malignancy, generally associated with continuous occupational exposure to asbestos. Only a multimodal-approach to treatment, based on surgical resection, chemotherapy and\/or radiation, has shown some benefits. However, the survival rate remains low. Nimotuzumab (h-R3), an anti-EGFR (epidermal growth factor receptor) humanized antibody, is proposed as a promising agent for the treatment of MPM. The aim of this research was to implement a procedure for nimotuzumab radiolabeling to evaluate its biodistribution and affinity for EGF (epidermal growth factor) receptors present in a mesothelioma xenograft. Nimotuzumab was radiolabeled with 67Ga; radiolabel efficiency, radiochemical purity, serum stability, and biodistribution were evaluated. Biodistribution and tumor uptake imaging studies by microSPECT\/CT in mesothelioma xenografts revealed constant nimotuzumab uptake at the tumor site during the first 48 h after drug administration. In vivo studies using MPM xenografts showed a significant uptake of this radioimmunoconjugate, which illustrates its potential as a biomarker that could promote its theranostic use in patients with MPM.<\/jats:p>","DOI":"10.3390\/molecules23123138","type":"journal-article","created":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T11:47:53Z","timestamp":1543492073000},"page":"3138","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Biodistribution and Tumor Uptake of 67Ga-Nimotuzumab in a Malignant Pleural Mesothelioma Xenograft"],"prefix":"10.3390","volume":"23","author":[{"given":"Vanessa","family":"Izquierdo-S\u00e1nchez","sequence":"first","affiliation":[{"name":"Secci\u00f3n de Estudios de Posgrado e Investigaci\u00f3n, Escuela Superior de Medicina, Instituto Polit\u00e9cnico Nacional, Ciudad de M\u00e9xico 11340, Mexico"},{"name":"Unidad de Investigaci\u00f3n Biom\u00e9dica en C\u00e1ncer, INCan\/UNAM, Instituto Nacional de Cancerolog\u00eda (INCan), Ciudad de M\u00e9xico 14080, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sa\u00e9","family":"Mu\u00f1iz-Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Laboratorio de Oncolog\u00eda Experimental, Subdirecci\u00f3n de Investigaci\u00f3n B\u00e1sica, Instituto Nacional de Cancerolog\u00eda, Ciudad de M\u00e9xico 14080, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3799-1499","authenticated-orcid":false,"given":"H\u00e9ctor","family":"V\u00e1zquez-Becerra","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n Biom\u00e9dica en C\u00e1ncer, INCan\/UNAM, Instituto Nacional de Cancerolog\u00eda (INCan), Ciudad de M\u00e9xico 14080, Mexico"},{"name":"Instituto de F\u00edsica, Universidad Nacional Aut\u00f3noma de M\u00e9xico (UNAM), Ciudad de M\u00e9xico 04510, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Pacheco-Yepez","sequence":"additional","affiliation":[{"name":"Secci\u00f3n de Estudios de Posgrado e Investigaci\u00f3n, Escuela Superior de Medicina, Instituto Polit\u00e9cnico Nacional, Ciudad de M\u00e9xico 11340, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario E.","family":"Romero-Pi\u00f1a","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n Biom\u00e9dica en C\u00e1ncer, INCan\/UNAM, Instituto Nacional de Cancerolog\u00eda (INCan), Ciudad de M\u00e9xico 14080, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oscar","family":"Arrieta","sequence":"additional","affiliation":[{"name":"Laboratorio de Oncolog\u00eda Experimental, Subdirecci\u00f3n de Investigaci\u00f3n B\u00e1sica, Instituto Nacional de Cancerolog\u00eda, Ciudad de M\u00e9xico 14080, Mexico"},{"name":"Unidad de Oncolog\u00eda Tor\u00e1cica, Instituto Nacional de Cancerolog\u00eda, Ciudad de M\u00e9xico 14080, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9301-5823","authenticated-orcid":false,"given":"Luis Alberto","family":"Medina","sequence":"additional","affiliation":[{"name":"Unidad de Investigaci\u00f3n Biom\u00e9dica en C\u00e1ncer, INCan\/UNAM, Instituto Nacional de Cancerolog\u00eda (INCan), Ciudad de M\u00e9xico 14080, Mexico"},{"name":"Instituto de F\u00edsica, Universidad Nacional Aut\u00f3noma de M\u00e9xico (UNAM), Ciudad de M\u00e9xico 04510, Mexico"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2018,11,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1159\/000339259","article-title":"Malignant Pleural Mesothelioma: From the Bench to the Bedside","volume":"83","author":"Astoul","year":"2012","journal-title":"Respiration"},{"key":"ref_2","first-page":"29","article-title":"Mesotelioma pleural maligno","volume":"28","year":"2005","journal-title":"An. Sist. Sanit. Navar."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11864-008-0067-z","article-title":"Mesothelioma Epidemiology, Carcinogenesis and Pathogenesis","volume":"9","author":"Yang","year":"2009","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1016\/j.ejca.2006.07.011","article-title":"Biology and management of malignant pleural mesothelioma","volume":"42","author":"Zucali","year":"2006","journal-title":"Eur. J. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Federico, R., Adolfo, F., Giuseppe, M., Lorenzo, S., Martino, D.T., Anna, C., Adriano, P., Gino, C., Francesca, R., and Matteo, C. (2013). Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma. BMC Cancer.","DOI":"10.1186\/1471-2407-13-22"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2147\/TCRM.S1603","article-title":"Review of pemetrexed in combination with cisplatin for the treatment of malignant pleural mesothelioma","volume":"4","author":"Goudar","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_7","first-page":"319","article-title":"Malignant pleural mesothelioma: Incidence, etiology, diagnosis, treatment, and occupational health","volume":"110","author":"Neumann","year":"2013","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.rmed.2009.07.019","article-title":"Pemetrexed in the treatment of malignant mesothelioma: Results from an expanded access program in Germany","volume":"104","author":"Reck","year":"2010","journal-title":"Respir. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1378\/chest.126.4.1318","article-title":"Malignant Pleral Mesothelioma, Update, Current Management, and Newer Therapeutic Strategies","volume":"126","author":"Pistolesi","year":"2004","journal-title":"Chest"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5274","DOI":"10.1158\/1078-0432.CCR-09-0062","article-title":"Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P","volume":"15","author":"Kreitman","year":"2010","journal-title":"Clin Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00280-014-2477-x","article-title":"High liposomal doxorubicin tumour tissue distribution, as determined by radiopharmaceutical labelling with (99 m)Tc-LD, is associated with the response and survival of patients with unresectable pleural mesothelioma treated with a combination of liposomal","volume":"74","author":"Arrieta","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00280-014-2429-5","article-title":"A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma","volume":"73","author":"Arrieta","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_14","first-page":"51","article-title":"New and emerging therapeutic options for malignant pleural mesothelioma: Review of early clinical trials","volume":"7","author":"Kotova","year":"2015","journal-title":"Cancer Manag. Res."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Rea, F., Favaretto, A., Marulli, G., Spaggiari, L., Martino, D.T., Ceribelli, A., Paccagnella, A., Crivellari, G., Russo, F., and Ceccarelli, M. (2011). Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma. J. Clin. Oncol.","DOI":"10.1200\/jco.2011.29.15_suppl.7090"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1053\/j.seminoncol.2006.04.003","article-title":"Epidermal growth factor receptor targeting in cancer","volume":"33","author":"Mendelsohn","year":"2006","journal-title":"Semin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/cncr.10372","article-title":"Monoclonal antibodies to target epidermal growth factor receptor-positive tumors","volume":"94","author":"Herbst","year":"2002","journal-title":"Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s11912-011-0177-9","article-title":"Malignant Pleural Mesothelioma","volume":"13","author":"Mason","year":"2011","journal-title":"Curr. Oncol. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/cncr.22552","article-title":"Update on the molecular biology of malignant mesothelioma","volume":"109","author":"Lee","year":"2007","journal-title":"Cancer"},{"key":"ref_20","first-page":"5242","article-title":"Inhibition of Epidermal Growth Factor Receptor Signaling in Malignant Pleural Mesothelioma","volume":"62","author":"Taffaro","year":"2002","journal-title":"Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/sj.bjc.6690650","article-title":"VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours","volume":"81","author":"Ohta","year":"1999","journal-title":"Br. J. Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"8690","DOI":"10.1016\/j.biomaterials.2013.07.100","article-title":"Epidermal growth factor receptor targeting in cancer: A review of trends and strategies","volume":"34","author":"Yewale","year":"2013","journal-title":"Biomaterials"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1586\/ers.10.17","article-title":"Translational therapies for malignant pleural mesothelioma","volume":"4","author":"Belli","year":"2010","journal-title":"Expert Rev. Resp. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1097\/00006231-200512000-00002","article-title":"Phase I\/II clinical trial of the humanized anti-EGF-r monoclonal antibody h-R3 labelled with 99mTc in patients with tumour of epithelial origin","volume":"26","author":"Torres","year":"2005","journal-title":"Nucl. Med. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"375","DOI":"10.4161\/cbt.5.4.2522","article-title":"Treatment of High-Grade Glioma Patients with the Humanized Anti-epidermal Growth Factor Receptor (EGFR) antibody h-R3","volume":"5","author":"Ramos","year":"2006","journal-title":"Cancer Biol. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Perez, R., Crombet, T., Leon, J., and Moreno, E. (2013). A view on EGFR-targeted therapies from the oncogene-addiction perspective. Front. Pharmacol.","DOI":"10.3389\/fphar.2013.00053"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00280-013-2277-8","article-title":"A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors","volume":"72","author":"Okamoto","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcancer.2011.12.009","article-title":"Monoclonal antibodies for the treatment of cancer","volume":"22","author":"Shuptrine","year":"2012","journal-title":"Semin. Cancer Biol."},{"key":"ref_29","unstructured":"Kowalsky, R.J., and Falen, S.W. (2004). Radiopharmaceuticals in Nuclear Pharmacy and Nuclear Medicine, American Pharmacists Association. [2nd ed.]."},{"key":"ref_30","first-page":"287","article-title":"Preclinical Evaluation of Lu-177-Nimotuzumab: A Potential Tool for Radioimmunotherapy of Epidermal Growth Factor Receptor-Overexpressing Tumors","volume":"26","author":"Vera","year":"2011","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10549-012-2137-y","article-title":"111In-Bn-DTPA-nimotuzumab with\/without modification with nuclear translocation sequence (NLS) peptides: An Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)\u2014resistant breast cancer","volume":"135","author":"Fasih","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_32","first-page":"141","article-title":"In vitro autoradiography of carcinoembryonic antigen in tissue from patients with colorectal cancer using multifunctional antibody TF2 and (67\/68Ga)-labeled haptens by pretargeting","volume":"2","author":"Hall","year":"2012","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ctrv.2010.11.004","article-title":"Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: Where do we stand?","volume":"37","author":"Agarwal","year":"2011","journal-title":"Cancer Treat. Rev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1590\/S1806-37132006000400011","article-title":"Morphological aspects as prognostic factors in malignant mesothelioma: A study of 58 cases","volume":"32","author":"Motta","year":"2006","journal-title":"J. Bras. Pneumol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.lungcan.2010.01.002","article-title":"Tissue and serum EGFR as prognostic factors in malignant pleural mesothelioma","volume":"70","author":"Gaafar","year":"2010","journal-title":"Lung Cancer."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0022-1759(83)90311-3","article-title":"The preparation of DTPA-coupled antibodies radiolabeled with metallic radionuclides: An improved method","volume":"65","author":"Hnatowich","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Vergara, I., Castillo, E.Y., Romero-pi\u00f1a, M.E., Torres-viquez, I., Paniagua, D., Boyer, L.V., Alag\u00f3n, A., and Medina, L.A. (2016). Biodistribution and Lymphatic Tracking of the Main Neurotoxin of Micrurus fulvius Venom by Molecular Imaging. Toxins, 8.","DOI":"10.3390\/toxins8040085"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S1380-2933(97)00065-1","article-title":"Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: Recovery of antagonistic activity","volume":"3","author":"Mateo","year":"1997","journal-title":"Immunotechnology"},{"key":"ref_39","unstructured":"Sandana, G., John, M., Rose, C., Takeuchi, S., John, G.S.M., Rose, C., and Takeuchi, S. (2011). Understanding Tools and Techniques in Protein Structure Prediction. Syst. Comput. Biol. Bioinform. Comput. Model."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/sj.bjp.0705915","article-title":"Preclinical characterisation of 111 In-DTPA-trastuzumab","volume":"143","author":"Marjolijn","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/jlcr.2988","article-title":"Preclinical evaluation of radiolabelled nimotuzumab, a promising monoclonal antibody targeting the epidermal growth factor receptor","volume":"56","author":"Barta","year":"2013","journal-title":"J. Label. Compd. Radiopharm."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1073\/pnas.75.7.3317","article-title":"Visualization by fluorescence of the binding and internalization of epidermal growth factor in human carcinoma cells A-431","volume":"75","author":"Haigler","year":"1978","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.apradiso.2015.05.001","article-title":"131I-Nimotuzumab\u2014A potential radioimmunotherapeutic agent in treatment of tumors expressing EGFR","volume":"102","author":"Kameswaran","year":"2015","journal-title":"Appl. Radiat. Isot."},{"key":"ref_44","unstructured":"Berrozpe, J.D., Lanao, J.M., and Delfina, J.M.P. (2001). Biofarmacia y Farmacocin\u00e9tica Vol: II, Editorial Sintesis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0969-8051(97)00139-X","article-title":"Pharmacokinetics, biodistribution and dosimetry of 99mTc-labeled anti-human epidermal growth factor receptor humanized monoclonal antibody R3 in rats","volume":"25","author":"Morales","year":"1998","journal-title":"Nucl. Med. Biol."},{"key":"ref_46","unstructured":"Chopra, A. (2012). 177Lu-Labeled h-R3 (nimotuzumab), a humanized monoclonal antibody targeting the external domain of the epidermal growth factor receptor. Mol. Imaging Contrast Agent Database."},{"key":"ref_47","first-page":"2327","article-title":"Pharmacokinetics of therapeutic monoclonal antibodies used in oncology","volume":"25","author":"Wisniewski","year":"2005","journal-title":"Anticancer Res."},{"key":"ref_48","unstructured":"Keizer, R.J. (1980). Pharmacometrics in Early Clinical Drug Development. [Ph.D Thesis, Utrecht University]."},{"key":"ref_49","first-page":"164","article-title":"Kinetics of 67Ga compunds in brain sarcomas and kidneys of mice","volume":"14","author":"Konikowski","year":"1972","journal-title":"J. Nucl. Med."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Calvo, E., Walko, C., and Dees, E.C. (2016). Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics in the Era of Targeted Therapies. Am. Soc. Clin. Oncol. Educ.","DOI":"10.14694\/EDBK_159061"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Meibohm, B., and Derendorf, H. (2006). Pharmacokinetics and Pharmacodynamics of Biotech Drugs. Rev. Cell Biol. Mol.","DOI":"10.1002\/3527600906.mcb.200400105"},{"key":"ref_52","first-page":"1","article-title":"Diagnostic Efficacy and Safety of 99m Tc-Labeled Monoclonal Antibody Ior c5 in Patients with Colorectal and Anal Carcinomas ES SC RIB","volume":"6","author":"Pintado","year":"2007","journal-title":"Cancer Biol. Ther."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/23\/12\/3138\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:33:24Z","timestamp":1760196804000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/23\/12\/3138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,29]]},"references-count":52,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["molecules23123138"],"URL":"https:\/\/doi.org\/10.3390\/molecules23123138","relation":{},"ISSN":["1420-3049"],"issn-type":[{"type":"electronic","value":"1420-3049"}],"subject":[],"published":{"date-parts":[[2018,11,29]]}}}